We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Diabetes Testing on High-Throughput Analyzer Files for FDA Approval

By LabMedica International staff writers
Posted on 16 Mar 2016
Print article
Image: The cobas c513 analyzer provides throughput of up to 400 HbA1c patient results/hour, closed tube sampling (CTS), and is standardized according to IFCC transferable to DCCT/NGSP (Photo courtesy of Roche).
Image: The cobas c513 analyzer provides throughput of up to 400 HbA1c patient results/hour, closed tube sampling (CTS), and is standardized according to IFCC transferable to DCCT/NGSP (Photo courtesy of Roche).
The cobas c513 analyzer has been submitted to the US Food and Drug Administration (FDA) for approval as a dedicated, high-throughput HbA1c testing solution to help laboratories meet increasing testing needs for people with diabetes.

The cobas c513 analyzer from Roche (Basil, Switzerland) is based on the proven, trusted cobas technology developed in cooperation with Hitachi High-Technologies (HHT). The HbA1c test is a longer term measurement of blood sugar levels used to determine if a person has or is at risk of developing diabetes. Set to run on the established Tina-Quant HbA1c A1cDx Gen.3 test, which is also used across the Roche laboratory HbA1c portfolio, the cobas c513 will ensure high-quality results and comply with current guidelines and recommendations for HbA1c testing and measures A1c as defined by the IFCC.

cobas c513 features direct results reporting, thereby minimizing risk of result misinterpretation and eliminating the need to perform time-consuming, manual result interpretation. This feature will help save valuable time and laboratory resources, while ensuring high-quality results. Furthermore, cobas c513 will provide a higher on-board test capacity, enabling laboratories to load the analyzer with more tests at a time, save lab space, minimize resources, and ensure a smooth workflow. It offers closed tube sampling, which will reduce hands-on time, prevent sample contamination, and ensure operator safety for laboratory personnel.

The prevalence of diabetes has increased, with estimates of as many as 566 million people with diabetes worldwide, of which 32% may still be undiagnosed. The total number of people with diabetes is anticipated to increase by 53% until 2035. Over half of all cases are preventable.

"As the prevalence and incidence of diabetes continues to grow, it's estimated that by the end of this decade 15% of American adults—or roughly 39 million people will be affected. This staggering number is not only a major cause for concern for healthcare providers, but for healthcare organizations as well," said Dr. Alan Wright, Chief Medical Officer, Roche Diagnostics Corporation, "With the submission of the cobas c513 analyzer to the FDA for 510(k) clearance, Roche is dedicated to helping address the need to quickly identify, diagnose, and monitor people with diabetes."

Upon receiving FDA clearance, Roche plans to replace its existing analyzer, the COBAS INTEGRA 800 CTS, which has been a successful and well-established solution. The cobas c513 analyzer will further increase efficiency by doubling the already market-leading throughput of the COBAS INTEGRA 800 CTS from 200 to 400 patient results per hour. cobas c513 will achieve this performance with the same space footprint.

Related Links:

Roche
Cobas Analyzers & Tests


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.